EPHA1: IHC Expression in Cancer and Radioligand Target Profile
EPHA1, EPH receptor A1, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, EPHA1 staining is highest in colorectal cancer (100% of samples positive), endometrial cancer (100% of samples positive) and thyroid cancer (100% of samples positive). Evidence on whether EPHA1 internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is EPHA1 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze EPHA1 freeIs EPHA1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in colorectal cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
EPHA1 IHC staining by cancer type
Protein expression of EPHA1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Colorectal Cancer | 0.83 | High | 100% |
| Endometrial Cancer | 0.69 | High | 100% |
| Thyroid Cancer | 0.67 | High | 100% |
| Neuroendocrine Tumors | 0.67 | High | 100% |
| Pancreatic Cancer | 0.67 | High | 100% |
| Prostate Cancer | 0.67 | High | 100% |
| Testicular Cancer | 0.67 | High | 100% |
| Liver Cancer | 0.67 | High | 100% |
| Bladder Cancer | 0.64 | High | 100% |
| Ovarian Cancer | 0.61 | High | 100% |
| Breast Cancer | 0.61 | High | 100% |
| Gastric Cancer | 0.61 | High | 100% |
| Melanoma | 0.58 | High | 100% |
| Kidney Cancer | 0.58 | High | 100% |
| Head and Neck Cancer | 0.56 | High | 100% |
| Skin Cancer | 0.53 | High | 100% |
| Cervical Cancer | 0.53 | High | 83% |
| Lung Cancer | 0.48 | Medium | 91% |
| Glioma | 0.21 | Medium | 64% |
| Lymphoma | 0.08 | Low | 25% |
Is EPHA1 internalized?
Uncertain. The abstracts mention EPHA1 in the context of endocytosis and immune response genes related to Alzheimer's disease but do not provide direct evidence regarding whether EPHA1 undergoes internalization or endocytosis upon ligand/antibody binding.
Sources: PMID 26517285 · PMID 23686306. AI-extracted from abstracts, so verify before citing.
EPHA1 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for EPHA1 yet. Search ClinicalTrials.gov for EPHA1 trials.
EPHA1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See EPHA1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
EPHA1 gene essentiality (DepMap)
CRISPR knockout effect across 1257 cancer cell lines: -0.04 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related colorectal cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EGFR · FAP · CEA (CEACAM5) · EPCAM · SSTR2 · STEAP2
See all radioligand therapy targets in colorectal cancer.
See how EPHA1 ranks against 15,000 targets for your indication.
Analyze EPHA1 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.